Print-Friendly PDF Print this page

Mitchell Bloom is national co-chair of Goodwin Procter’s Life Sciences Practice. Mr. Bloom specializes in representing public and private life science companies, as well as venture capital firms and investment banks focused on the life sciences sector, including matters involving biotechnology, medical devices, diagnostics and healthcare information technology.

Chambers USA: America’s Leading Lawyers for Business, The Legal 500 and LMG Life Sciences have all recognized Mr. Bloom as a national industry leader for his corporate finance and life sciences expertise.

Mr. Bloom's practice is focused on the representation of emerging and public life science companies, and he currently serves as principal outside or general counsel to numerous companies. In addition to day-to-day corporate counseling and strategic advice to his clients, he regularly handles a variety of major business transactions, including public offerings, mergers and acquisitions, venture capital financings and strategic collaborations and commercial transactions.

His recent client representations include work with:

  • Voyager Therapeutics in its strategic collaboration with Genzyme for $100 million upfront and up to $745 million in milestone payments
  • Alnylam Pharmaceuticals in its $450 million follow-on public offering
  • Zafgen in its $96 million initial public offering, $137 million follow-on public offering, and earlier $45 million Series E financing
  • DBV Technologies in its $92 million initial public offering
  • ProQR Therapeutics B.V in its $97.5 million initial public offering
  • BMO Capital Markets, Stifel and William Blair in connection with Tokai Pharmaceuticals’ $97 million initial public offering
  • SAGE Therapeutics in its $90 million initial public offering
  • Bank of America and Leerink Swann in connection with Roka Biosciences’ $60 million initial public offering
  • Alnylam Pharmaceuticals in its strategic alliance and $700 million equity financing with Genzyme
  • J.P. Morgan in connection with Intrexon Corporation’s $160 million initial public offering, one of the largest biotech IPOs in history
  • Esperion in its $70 million initial public offering and $175 million follow-on offering
  • OCERA Therapeutics in its recent $25 million public offering and previous $28 million PIPE transaction
  • Voyager Therapeutics in its $45 million Series A financing
  • Jounce Therapeutics, Inc. in the closing of its $47 million financing
  • Mevion Medical Systems in connection with a $55 million in equity and debt financing to advance the company’s proton therapy system, MEVION S250
  • Underwriters in Regulus Therapeutics' initial and follow-on public offerings
  • Nimbus Therapeutics in connection with innovative collaborations with Monsanto and Shire Plc
  • Warp Drive Bio in its innovative strategic partnership with Sanofi

Mr. Bloom is recognized nationally for his leadership in the life sciences industry and has been included in numerous legal guides for his corporate finance and life sciences expertise, including Chambers USA: America’s Leading Lawyers for Business, U.S. News-Best Lawyers and The Legal 500 United States. In addition, for the past two years he has been selected as a “Life Science Star” by LMG Life Sciences.

Under his leadership, Goodwin Procter’s Life Sciences Practice has received numerous awards and honors, including U.S. News’ Biotechnology Law Firm of the Year for three years running (2013-2015) and perennial nationwide recognition by Chambers USA.

Prior to joining Goodwin Procter, Mr. Bloom was a partner at Testa, Hurwitz & Thibeault in Boston, where he was a member of the Business Practice Group and co-chair of its Life Sciences Practice.

Mr. Bloom is a member of the American, Massachusetts and Boston Bar Associations.

A New Paradigm for Venture Funds
The Metropolitan Corporate Counsel
September 1, 2007